Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

24 Apr 2024

Abstract excerpt

PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Renal cell carcinoma treatment
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38657187
DOI: 10.1200/jco.23.01983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerPMID 38657187Read ↗

Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity Read ↗

Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin ResistanceSemantic proximity Read ↗

Defining biologically directed therapy target signatures in urothelial carcinoma: A transcriptomic framework for precision therapySemantic proximity Read ↗

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity Read ↗

The genomic and transcriptomic landscape of metastastic urothelial cancer.Semantic proximity Read ↗

Associations of TACSTD2/ TROP2 and NECTIN‐4/ NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohortsSemantic proximity Read ↗

TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinomaSemantic proximity Read ↗

The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.Semantic proximity Read ↗

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.Semantic proximity Read ↗

Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68 Ga-N188Semantic proximity Read ↗

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.Semantic proximity Read ↗

ERBB2 /HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.